Traditional Medicine Research published an article entitled Study of the anti-inflammatory effect of the Traditional Mongolian Medicine Hohgardi-9 in acute lung injury on 01 August 2023.The author confirmed this arti...Traditional Medicine Research published an article entitled Study of the anti-inflammatory effect of the Traditional Mongolian Medicine Hohgardi-9 in acute lung injury on 01 August 2023.The author confirmed this article’s proof on 31 July 2023 without any questions.But on 06 January 2025,the editorial team found an inconsistency between the number of SD rats purchased(n=20)and the sample size used in the experiment(n=50).展开更多
(The Innovation 4,100380;January 30,2023)In the originally published version of this article,we,the authors,inadvertently included the wrong image for the aged group in Figure 5A(spinal vGM column).This does not affec...(The Innovation 4,100380;January 30,2023)In the originally published version of this article,we,the authors,inadvertently included the wrong image for the aged group in Figure 5A(spinal vGM column).This does not affect the discussions or conclusions of the paper,and we deeply regret this oversight.The correct figure has been incorporated in the original paper online.展开更多
To the Editor:After chimeric antigen receptor T(CAR-T)cell therapy,over 90%of patients experience either mild or severe cytopenia,with the prevalence of Grades 3–4 neutropenia ranging from 53%to 94.3%.[1,2]Granulocyt...To the Editor:After chimeric antigen receptor T(CAR-T)cell therapy,over 90%of patients experience either mild or severe cytopenia,with the prevalence of Grades 3–4 neutropenia ranging from 53%to 94.3%.[1,2]Granulocyte colony-stimulating factor(G-CSF),known for its ability to enhance the proliferation and differentiation of neutrophils,has been extensively employed for the prevention and treatment of neutropenia in various contexts.However,its application in patients with refractory/relapsing B-cell acute lymphoblastic leukemia(R/R B-ALL)after CAR-T cell therapy remains a topic of debate.[3]Several studies have suggested that G-CSF may exert anti-inflammatory effects by modulating the release of inflammatory factors,such as interleukin-12(IL-12),TNF-α,and IFN-γ,or by influencing the differentiation of T-cell subsets.[4]However,other researchers have posited that G-CSF could exacerbate cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS)through the augmentation of antigen-presenting cell function.展开更多
文摘Traditional Medicine Research published an article entitled Study of the anti-inflammatory effect of the Traditional Mongolian Medicine Hohgardi-9 in acute lung injury on 01 August 2023.The author confirmed this article’s proof on 31 July 2023 without any questions.But on 06 January 2025,the editorial team found an inconsistency between the number of SD rats purchased(n=20)and the sample size used in the experiment(n=50).
文摘(The Innovation 4,100380;January 30,2023)In the originally published version of this article,we,the authors,inadvertently included the wrong image for the aged group in Figure 5A(spinal vGM column).This does not affect the discussions or conclusions of the paper,and we deeply regret this oversight.The correct figure has been incorporated in the original paper online.
基金supported by grants from the General Project of the National Natural Science Foundation of China(No.81970180)the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022QN030)+7 种基金the Key projects of Tianjin Applied Basic Research and Multi-Investment Fund(No.21JCZDJC01240)the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022XK018)Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-056B)Tianjin Municipal Natural Science Foundation(No.22JCQNJC00820)Tianjin Health Research Project(No.TJWJ2023QN027)Tianjin Health Bureau Project(No.ZC20074)Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJWJ2023XK010)Henan Provincial Youth and Middle-aged Health Science and Technology Talents Excellent Youth Program(No.20230273).
文摘To the Editor:After chimeric antigen receptor T(CAR-T)cell therapy,over 90%of patients experience either mild or severe cytopenia,with the prevalence of Grades 3–4 neutropenia ranging from 53%to 94.3%.[1,2]Granulocyte colony-stimulating factor(G-CSF),known for its ability to enhance the proliferation and differentiation of neutrophils,has been extensively employed for the prevention and treatment of neutropenia in various contexts.However,its application in patients with refractory/relapsing B-cell acute lymphoblastic leukemia(R/R B-ALL)after CAR-T cell therapy remains a topic of debate.[3]Several studies have suggested that G-CSF may exert anti-inflammatory effects by modulating the release of inflammatory factors,such as interleukin-12(IL-12),TNF-α,and IFN-γ,or by influencing the differentiation of T-cell subsets.[4]However,other researchers have posited that G-CSF could exacerbate cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS)through the augmentation of antigen-presenting cell function.
